Serengen GmbH and Deargen Inc. have established a collaboration to accelerate the drug discovery process by bringing together Serengen’s novel DNA encoded library (DEL) technology with Deargen’s artificial intelligence (AI)-driven drug discovery platform, Deardti.
Two papers published in Nature on Aug. 23, 2023, describe brain computer interfaces (BCI) with unprecedented capabilities for decoding brain activity into sentences, translating at speeds around half that of normal speech, and with vocabularies exceeding 1,000 words.
3Z ehf and Biotx.ai AG have established a strategic partnership to help advance the development of drugs for attention deficit hyperactivity disorder (ADHD).
Insilicotrials Technologies SpA has entered into a collaborative partnership with Axoltis Pharma SA in the field of central nervous system (CNS) diseases, with the aim of optimizing the clinical development plan for Axoltis’ drug candidate, NX-210c.
The U.S. Senate held a July 25 hearing on the need for regulation of artificial intelligence (AI), which highlighted an interest in a single overarching agency that would direct any regulations promulgated for AI across the U.S. economy.
Artificial intelligence (AI) continues to entice. On the exhibition floor at the 2023 Congress of the European Academy of Neurology, one company’s booth featured “Mindart” technology. A passersby could answer a short series of prompts, and get a unique image based on the input made by generative AI. Entertainment aside, medically speaking, AI applications “are still research,” Riccardo Soffietti told his audience at one of several sessions devoted to AI. “But obviously, research is the future.”
Lantern Pharma Inc. has entered into a research collaboration with Bielefeld University to develop antibody-drug conjugates (ADCs) with therapeutic and antitumor potential. Using Lantern’s proprietary artificial intelligence (AI) platform, RADR, the collaboration will leverage insights from the recently developed RADR AI ADC module in combination with research from Bielefeld.
Iktos SA and Curreio Inc. have established a collaboration agreement using artificial intelligence (AI) for new drug design. Under this collaboration, Iktos will leverage its de novo generative design technology in combination with Curreio’s cryo-electron microscopy (EM) platform to facilitate the rapid design of novel preclinical drug candidates for an undisclosed target.
RSS
